Behçet disease-associated uveitis successfully treated with golimumab

Ocular Immunology and Inflammation

Volumn 21, Issue 2, 2013, Pages 160-162

  Mesquida, Marina ^a   Victoria Hernández, María ^a   Llorenç, Victor ^a   Pelegrín, Laura ^a   Espinosa, Gerard ^a   Dick, Andrew D ^b   Adán, Alfredo ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Anti TNF; Beh et's Disease; Golimumab; Infliximab; Uveitis

Indexed keywords

CYCLOSPORIN A; GOLIMUMAB; INFLIXIMAB; PREDNISONE;

ADULT; ANTIBODY PRODUCTION; ARTICLE; BEHCET DISEASE; BIOLOGICAL THERAPY; CASE REPORT; DISEASE ASSOCIATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; EYE EXAMINATION; EYE SYNECHIA; FLUORESCENCE ANGIOGRAPHY; HUMAN; IDIOPATHIC DISEASE; MALE; PATIENT REFERRAL; REFRACTORY PERIOD; RELAPSE; REMISSION; RETINA VASCULITIS; SLIT LAMP; UVEITIS; VISUAL ACUITY;

ADULT; ANTIBODIES, MONOCLONAL; BEHCET SYNDROME; HUMANS; MALE; TUMOR NECROSIS FACTOR-ALPHA; UVEITIS;

EID: 84876004363     PISSN: 09273948     EISSN: 17445078     Source Type: Journal    
DOI: 10.3109/09273948.2012.741744     Document Type: Article

References (11)

1. Perra D, Alba MA, Callejas JL, et al. Adalimumab for the treatment of Behcet's disease: Experience in 19 patients. Rheumatology (Oxford). 2012 [Epub ahead of print
2. Lee RW, Dick AD. Treat early and embrace the evidence in favour of anti-TNF-Alpha therapy for Behçet's uveitis. Br J Ophthalmol. 2010;94:269-270
3. Keystone E, Genovese MC, Klareskog L, et al. Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GOFORWARD study. Ann Rheum Dis. 2010;69:1129-1135
4. Braun J, Deodhar A, Inman RD, et al. Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study. Ann Rheum Dis. 2012;71:661-667
5. Kavanaugh A, van der Heijde D, McInnes IB, et al. Golimumab in psoriatic arthritis: One-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial. Arthritis Rheum. 2012;64:2504-2517
6. Jabs DA, Nussenblatt RB, Rosenbaum JT; Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005;140:509-516
7. Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-Tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial. ATTRACT Study Group. Lancet. 1999;354:1932-1939
8. Okada AA, Goto H, Ohno S, et al. Ocular Behçet's Disease Research Group of Japan. Multicenter study of infliximab for refractory uveoretinitis in Behçet disease. Arch Ophthalmol. 2012;130:592-598
9. Smolen JS, Kay J, Landewé RB, et al. Golimumab in patients with active rheumatoid arthritis who have previous experience with tumour necrosis factor inhibitors: Results of a long-Term extension of the randomised, doubleblind, placebo-controlled GO-AFTER study through week 160. Ann Rheum Dis. 2012 [Epub ahead of print
10. Cordero-Coma M, Salom D, Diaz-Llopis M, et al. Golimumab for uveitis. Ophthalmology. 2011;118:e3-e4
11. William M, Faez S, Papaliodis GN, et al. Golimumab for the treatment of refractory juvenile idiopathic arthritis-Associated uveitis. J Ophthalmic Inflamm Infect. 2012 [Epub ahead of print